Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High – Here’s What Happened

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $15.48 and last traded at $15.57, with a volume of 440107 shares trading hands. The stock had previously closed at $14.69.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AMRX shares. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. UBS Group assumed coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective on the stock. Barclays lifted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.80.

Amneal Pharmaceuticals Price Performance

The firm has a market cap of $4.87 billion, a PE ratio of 40.24 and a beta of 1.30. The stock has a 50-day moving average price of $12.82 and a 200 day moving average price of $13.02.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The firm had revenue of $722.52 million for the quarter. As a group, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 17.30% of the stock is currently owned by insiders.

Institutional Trading of Amneal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Spire Wealth Management raised its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares during the period. Intech Investment Management LLC grew its stake in Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after buying an additional 1,159 shares during the period. Hsbc Holdings PLC increased its position in shares of Amneal Pharmaceuticals by 1.6% in the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Amneal Pharmaceuticals by 2.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Comerica Bank raised its stake in shares of Amneal Pharmaceuticals by 56.1% in the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock valued at $59,000 after acquiring an additional 1,685 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.